Novo Nordisk to boost obesity drugs manufacturing capacity
Advertisement
Frankfurt: Novo Nordisk said it will boost manufacturing capacity for future obesity drug launches and worry less about marketing and advertising after a bungled market introduction of its Wegovy injection last year.
"As we look to launch future products, obviously we will take into consideration more of a 'pull' than a 'push' commercial strategy. And that links into how we scale capacity for that," Chief Executive Lars Fruergaard Jorgensen told journalists in a call on nine-month results.
"We see this pull nature in the market for anti-obesity medicine, which is fantastic because we have the broadest portfolio in the industry to do that," he added.
The company is in a drawn-out production revamp after a contractor filling Wegovy injection pens ran into problems late last year.
Read also: Novo Nordisk Eptacog alfa gets CDSCO panel nod for Additional Indication
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.